YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Erectile Dysfunction
Conditions
Erectile Dysfunction
Trial Timeline
Nov 1, 2011 → Mar 1, 2013
NCT ID
NCT01423370About YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo
YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo is a phase 2 stage product being developed by Yuhan for Erectile Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT01423370. Target conditions include Erectile Dysfunction.
What happened to similar drugs?
11 of 20 similar drugs in Erectile Dysfunction were approved
Approved (11) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01423370 | Phase 2 | Completed |
Competing Products
20 competing products in Erectile Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tadalafil + placebo | Eli Lilly | Phase 3 | 40 |
| Tacrolimus + Placebo | Astellas Pharma | Approved | 43 |
| Mirabegron | Astellas Pharma | Phase 1/2 | 32 |
| LY2452473 + Tadalafil + LY900010 | Eli Lilly | Phase 1 | 29 |
| tadalafil + placebo | Eli Lilly | Phase 3 | 40 |
| tadalafil | Eli Lilly | Phase 3 | 40 |
| LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473) | Eli Lilly | Phase 2 | 35 |
| Tadalafil | Eli Lilly | Approved | 43 |
| tadalafil + placebo | Eli Lilly | Approved | 43 |
| Tadalafil + Sildenafil Citrate | Eli Lilly | Approved | 43 |
| Tadalafil + Placebo | Eli Lilly | Phase 3 | 40 |
| Placebo + Tadalafil | Eli Lilly | Approved | 43 |
| Tadalafil + Placebo | Eli Lilly | Approved | 43 |
| tadalafil | Eli Lilly | Approved | 43 |
| Tadalafil + Sildenafil | Eli Lilly | Approved | 43 |
| tadalafil once a day [T(OaD)] + sildenafil citrate as needed [S(PRN)] + tadalafil as needed [T(PRN)] | Eli Lilly | Phase 3 | 40 |
| Tadalafil + Placebo | Eli Lilly | Approved | 43 |
| Dapoxetine | Johnson & Johnson | Phase 3 | 40 |
| dapoxetine | Johnson & Johnson | Phase 3 | 40 |
| Placebo + Dapoxetine + PDE5I (phosphodiesterase-5 inhibitor) | Johnson & Johnson | Phase 3 | 40 |